VEGFR2 / NFAT Reporter - HEK293 Recombinant Cell Line

VEGFR2 / NFAT Reporter - HEK293 Recombinant Cell Line
SKU
BPS79387
Packaging Unit
2 vials
Manufacturer
BPS Bioscience

Availability: loading...
Price is loading...
Products from BPS Bioscience require a minimum order value above 400€

Applications: Screen for inhibitors of VEGF/VEGFR2 signaling in a cellular context Screen for inhibitors of kinase activity of VEGFR2 in a cellular context

Background: VEGF (Vascular Endothelial Growth Factor)/VEGFR (Vascular Endothelial Growth Factor Receptor) interaction is an important mediator of angiogenesis as well as cell survival and proliferation. VEGFR2 is a tyrosine receptor kinase that plays a major role in cellular responses driven by VEGF. Targeting the kinase activity of VEGFR2 has been an attractive tool in cancer therapy based on its anti-angiogenesis effects. In addition to the kinase inhibitors, humanized monoclonal antibodies interfering with VEGF/VEGFR2 interaction have been also developed for anti-cancer treatments.

Description: Recombinant HEK-293 cells expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of human VEGFR2 (Human Vascular Endothelial Growth Factor Receptor 2; KDR, FLK1; ref seq. NM_002253.1).

Host Cell Line: HEK293

Mycoplasma Testing: The cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich, #MP0025) to confirm the absence of Mycoplasma species.

Storage Stability: Immediately upon receipt, store vials in liquid nitrogen.

Supplied As: Each vial contains 2 x 106 cells in 1 ml of 10% DMSO.

Warnings: Avoid freeze/thaw cycles.

Biosafety Level: BSL-2
More Information
SKU BPS79387
Manufacturer BPS Bioscience
Manufacturer SKU 79387
Package Unit 2 vials
Quantity Unit PAK
Host Human
Product information (PDF) Download
MSDS (PDF)
×